



Incidence of thrombophilia in patients with recurrent pregnancy loss.

Dr Ganesh Bharaswadkar

Matoshri,shreyanagar, Aurangabad,Maharashtra,India

Abstract:

Background: Approximately 1-3% of women of reproductive age suffer from recurrent pregnancy loss.

Objective of this study was to evaluate the association between recurrent pregnancy loss and thrombophilia.

Methods: This is a descriptive study, involving retrospective analysis of patients with recurrent pregnancy losses.

Patients with recurrent pregnancy loss in whom associated morbidity factors were excluded underwent screening for both acquired and inherited thrombophilia. Results: A total of 20 patients were screened for acquired and inherited thrombophilia with recurrent pregnancy loss.


Thrombophilia was diagnosed in 70% cases. Out of which, anticardiolipin antibodies was found positive in 57% of patients, protein C 7% and protein S deficiency was observed in 35% cases.

Conclusions: Thrombophilias are associated with recurrent pregnancy loss. Patients in whom other associated morbid factors are excluded, should be offered screening for thrombophilia.

Multidisciplinary management involving hematologist is vital for management.

Biography:

Dr Ganesh Bharaswadkar (Sai Krupa Hospital) in Pune treats the various ailments of the patients by helping them undergo high-quality treatments and procedures. Among the numerous services offered here, the clinic provides treatments for Uterine Fibroids or Myomas, Ovarian Cysts, Endometriosis, Pelvic Organ Prolapse, Urinary Problems, Vaginal Discharge, Subfertility, Menopause, Gynaecological Cancers, Abnormal Pap Smears - Pre-Invasive Cervical/Vaginal Disease and Vulva Conditions. The doctor is also listed under Gynaecologist & Obstetrician Doctors. Furthermore, the patients also visit the clinic for Contraception Advice, HPV Tests, and Biopsy Tests etc.



Publication of speakers:

1. Bharaswadkar, Ganesh. (2020). Role of neo-adjuvant chemotherapy followed by surgery in cervical cancer: a review. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 9. 3912. 10.18203/2320-1770.ijrcog20203884.
2. Prakash G, Kumar L. Chemotherapy for cervical cancer: an update; in Rajaram S (ed): *cancer cervix*, edition 1st. New Delhi, Jaypee Brothers Medical Publishers Pvt. Ltd.; 2011:214.
3. Sharma A, Kumar L. Cancer of the cervix: what is better?. *Natl Med J India*. 2018;31:97-8.
4. Sananes C, Giaroli A, Soderini A, Guardado N, Snaidas L, Bermudez A, et al. Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cervix uteri: long-term follow-up of a pilot study. *Eur J Gynaecol Oncol*. 1998;19:368-73.
5. Hwang YY, Moon H, Cho SH, Kim KT, Moon YJ, Kim SR, et al. Ten-year survival of patients with locally advanced, stage ib-iiib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. *Gynecol Oncol*. 2001;82:88-93.
6. Chang TC, Lai CH, Hong JH, Hsueh S, Huang KG, Chou HH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin and radical hysterectomy versus radiation therapy for bulky IB and IIA cervical cancer. *J Clin Oncol*. 2000;18:1740-7.

[International Experts Meet on Gynecology and Womens Health | August 19-20, 2021 | London, UK](#)

Citation: Ganesh Bharaswadkar; Incidence of thrombophilia in patients with recurrent pregnancy loss; *Women Health and Wellness 202*; August 19-20, 2021; London, UK